Related Experiment Videos
Genetics of multiple myeloma.
Michaela J Higgins1, Rafael Fonseca
1Department of Internal Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85258, USA.
Best Practice & Research. Clinical Haematology
|July 20, 2005
Summary
Advances in plasma cell neoplasm genetics reveal two main pathways: hyperdiploidy and immunoglobulin heavy chain (IgH) translocations. Genetic markers like chromosome 13 abnormalities are linked to shorter survival, guiding targeted therapies.
Area of Science:
- Genetics and Cytogenetics
- Oncology
- Molecular Biology
Background:
- Plasma cell neoplasms, including multiple myeloma (MM), exhibit complex genetic and cytogenetic abnormalities.
- Recent research has significantly expanded our understanding of these genetic underpinnings.
- These genetic insights are crucial for understanding disease pathophysiology and clinical implications.
Purpose of the Study:
- To review recent advances in the genetics and cytogenetics of plasma cell neoplasms.
- To integrate these findings within the pathophysiologic context of the disease.
- To discuss the clinical implications of identified genetic abnormalities.
Main Methods:
- Review of gene expression profiling strategies.
- Analysis of karyotype and molecular cytogenetics data.
- Integration of genetic studies to define disease subgroups.
Main Results:
- Plasma cell tumors follow two primary pathogenetic pathways: hyperdiploidy and chromosome translocations involving the immunoglobulin heavy chain (IgH) locus.
- Gene expression profiling confirms subgroups identified by cytogenetic and genetic studies.
- Specific genetic markers, including chromosome 13 abnormalities, hypodiploidy, and chromosome 1 abnormalities, are associated with shortened survival.
- Recurrent translocations involving the IgH locus occur in 40-50% of patients.
- Similar translocations are observed in monoclonal gammopathy of undetermined significance (MGUS).
Conclusions:
- Plasma cell neoplasms can be classified into distinct subgroups based on genetic profiles.
- Identification of critical genetic lesions is essential for developing targeted therapies.
- Understanding the genetic landscape of MM and MGUS can inform prognosis and treatment strategies.